Autolus Therapeutics plc has 10 Schedule 13D or 13G filings on record since 2025-10-06. 3 holders' latest filing reports 5% or more of adss, each representing one ordinary share, nominal value $0.000042 per share, and ordinary shares, nominal value $0.000042 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| MAK Capital Fund LP | 12.6% | 33,621,487 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Armistice Capital, LLC | 5.64% | 15,000,000 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| PPF Group a.s. | 5.6% | 14,782,275 | SCHEDULE 13D/A, 2026-08-28 | 2026-08-27 |
| Deep Track Capital, LP | 0.97% | 2,568,613 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Wellington Management Group LLP | 0% | 0 | SCHEDULE 13G/A, 2025-10-06 | 2025-09-30 |
Purpose of Transaction (Item 4)
PPF Group a.s.
Item 4 of the Schedule 13D is hereby amended and supplemented to include the following: The transactions described in this Amendment No. 11 were undertaken solely to effect an internal reorganization of the PPF group of companies. Such transactions did not involve any change in the ultimate beneficial ownership of, or the ultimate voting or dispositive power over, the Ordinary Shares reported herein, and were not undertaken with any purpose of, or with the effect of, changing or influencing control of the Issuer. Other than as described herein, the Reporting Persons do not have any current plans or proposals which relate to or would result in any of the actions described in subparagraphs (a) through (j) above.Item 4 of the SCHEDULE 13D/A filed 2026-08-28
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-06 | Wellington Management Group LLP | 0% | SCHEDULE 13G/A |
| 2025-11-14 | Deep Track Capital, LP | 0.97% | SCHEDULE 13G/A |
| 2025-11-14 | Armistice Capital, LLC | 5.86% | SCHEDULE 13G |
| 2025-12-03 | MAK Capital Fund LP | 10.1% | SCHEDULE 13G/A |
| 2026-02-13 | MAK Capital Fund LP | 11.3% | SCHEDULE 13G/A |
| 2026-02-17 | Armistice Capital, LLC | 6.58% | SCHEDULE 13G/A |
| 2026-05-15 | Armistice Capital, LLC | 5.94% | SCHEDULE 13G/A |
| 2026-05-15 | MAK Capital Fund LP | 12.6% | SCHEDULE 13G/A |
| 2026-08-14 | Armistice Capital, LLC | 5.64% | SCHEDULE 13G/A |
| 2026-08-28 | PPF Group a.s. | 5.6% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Autolus Therapeutics plc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.